12 Investment Banks Helped OTC MicroCaps Uplist in Q2 2018


12 Investment Banks Helped OTC MicroCaps Uplist in Q2 2018

Uplisting from the OTC Markets to a senior US exchange, like the NASDAQ or NYSE American, is the goal of many microcap public companies trading on the OTC Markets. About one hundred out of the thousands of issuers listed on the OTC make the jump every year.

To uplist to a senior exchange issuers must meet a series of listing criteria. For microcaps, one of the most common paths to meeting listing criteria is obtaining a minimum level of shareholders equity. MicroCap issuers usually meet the shareholders equity threshold through a registered offering led by one or more investment banks.

In the second quarter of 2018, seven of the seventeen OTC Graduates worked with investment banks to complete significant equity raises in connection with their uplists to senior exchanges. Combined, these seven issuers raised $140.85 million.

Below, we look at the issuers and investment banks involved in those seven funding rounds.

Ticker Book Running Manager(s) Co-Manager(s) Amount Raised

Echelon Wealth Partners Inc.

  – $14,100,000
BCML FIG Partners, LLC D.A. Davidson & Co. $58,000,000.00
AMBO The Benchmark Company, LLC   – $7,650,000.00
ONCY Ladenburg Thalmann & Co. Inc.   – $8,900,000.00
GRNQ Network 1 Financial Securities, Inc.   – $3,200,000.00
OPRX Lake Street Capital Markets   – $9,000,000.00
ARPO  Guggenheim Securities Needham & Company

National Securities Corporation

H.C. Wainwright & Co.



Helius Medical Technologies, Inc. (Nasdaq: HSTD)

On April 11, 2018, HSTD uplisted from the OTCQB to the Nasdaq Capital Market. Helius Medical Technologies is a medical technology company focused on neurological wellness. Upon uplisting to the Nasdaq, HSTD closed a $14 million public offering. BTIG, LLC and Echelon Wealth Partners Inc. acted as joint book-running managers for the offering.

Learn more HERE.


BayCom Corp. (Nasdaq: BCML)

On May 4, 2018, BCML uplisted from the OTCBB to the Nasdaq Global Select Market. BCML, through its wholly owned operating subsidiary, United Business Bank, offers a full-range of loans, including SBA, FSA and USDA guaranteed loans, and deposit products and services to businesses and its affiliates in California, Washington and New Mexico.

In connection with the uplisting, BCML completed a $58 million underwritten public offering. FIG Partners, LLC acted as lead book-running manager with D.A. Davidson & Co. as joint book-running manager for the offering.

Learn more HERE


Ambow Education Holding Ltd. (NYSE American: AMBO)

On June 1, 2018, AMBO uplisted from the OTC to the NYSE American. Ambow Education Holding Ltd. is a leading national provider of educational and career enhancement services in China, offering high-quality, individualized services and products.

Upon uplisting to the NYSE American, AMBO closed a $7,650,000 public offering. The Benchmark Company, LLC acted as the sole book-running manager and representative of the underwriters of this offering.

Learn more HERE.


Oncolytics Biotech Inc. (Nasdaq: ONCY)

On June 1, 2018, ONCY uplisted from the OTCQX to the Nasdaq Capital Market. Oncolytics is a biotechnology company developing REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic virus.

Upon uplisting to the Nasdaq, ONCY completed a $8.9 million public offering. Ladenburg Thalmann & Co., acted as the sole book-running manager in connection with the Offering.

Learn more HERE.


Greenpro Capital Corp. (Nasdaq: GRNQ)

On June 13, 2018, GRNQ uplisted from the OTCQB to the Nasdaq Capital Market. GreenPro Capital Corp. is one of the fastest growing financial services company in Asia Pacific.

Upon uplisting to the Nasdaq, GRNQ closed a public offering of $3.2 million. Network 1 Financial Securities, Inc. acted as the placement agent for the offering.

Learn more HERE


OptimizeRx Corp. (Nasdaq: OPRX)

On June 22, 2018, OPRX uplisted from the OTCQB to the Nasdaq Capital Market. OptimizeRx is one of the nation’s leading providers of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers.

One month prior to uplisting, OPRX completed a $9 million private placement. Lake Street Capital Markets acted as the sole placement agent, and B. Riley FBR and ROTH Capital Partners acted as advisors to the transaction.

Learn more HERE


Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO)

On June 26, 2018, ARPO uplisted from the OTCQB to the Nasdaq Capital Market. Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases.

In connection with the uplist to the Nasdaq, ARPO completed a $40 million public offering. Guggenheim Securities acted as book-running manager for the offering. Needham & Company acted as lead manager, and National Securities Corporation and H.C. Wainwright & Co. acted as co-managers for the offering.

Learn more HERE



This post’s data was provided by Acquis Capital, LLC. Learn more at www.acquiscapital.com


Leave a Reply